Navigation Links
Genomma Lab Internacional Announces First Quarter 2009 Results
Date:4/28/2009

MEXICO CITY, April 28 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended March 31, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

    1Q09 Highlights (vs. 1Q08)
    -- Net Sales reached Ps. 649.1 million, an increase of 26.1%.
    -- Gross Profit was Ps. 477.3 million, an increase of 23.2%.
    -- EBITDA(1) increased 10.2% to Ps. 92.7 million.
    -- Consolidated Net Income rose 48.5% to Ps. 74.9 million.
    -- Earnings Per Share(2) increased 31.3% to Ps. 1.02 during the first
       quarter.
    -- International Net Sales rose 259.4%, to Ps. 115.4 million.
    -- During the first quarter, Genomma Lab successfully launched seven
       products under six existing brands (Base Brands(3) and Prior Year
       Launches(4)) as part of our line extension strategy.
    -- The Company also launched two products under two New Brands(5), as part
       of its new product launch plan during the first quarter.
    -- As of March 31, 2009 the Company had a net cash position of
       Ps. 1,078.6 million.
    -- During the first quarter of 2009, the Company also acquired Medicinas y
       Medicamentos Nacionales, S.A.P.I. de C.V. ("MMN"), a company with a
       broad product portfolio.

    (1) EBITDA is defined as earnings before interest, taxes, depreciation and
    amortization.
    (2) Earnings Per Share are for the last 12 months and were calculated
    using the weighted average of shares outstanding for the period.
    (3) Base Brands were launched at least two years prior to the last fiscal
    year (2007, 2006, 2005, etc.).
    (4) Prior Year Launches were brands launched during the prior fiscal year
    (2008).
    (5) New Brands were launched in the fiscal year just ended (2009)

For the complete version of this earnings report, please visit: www.genommalab.com

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

The Company had net sales of Ps. 2,629.4 million and EBITDA of Ps. 691.1 million in 2008. Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Relations Contact: Oscar Villalobo
    Tel: +52 (55) 5081 0000 Ext. 4250
    E-mail: inversion@genommalab.com

    In New York:  i-advize Corporate Communications, Inc.
    Tel: (212) 406-3692
    E-mail: genomma@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Genomma Lab Internacional Acquires UNIGASTROZOL
4. Genomma Lab Announces 2009 Earnings Guidance
5. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
6. Genomma Lab Announces Initiation of Stock Repurchase Fund
7. Genomma Lab, New Participant in Market-Maker Program
8. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
9. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
10. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
11. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
Breaking Medicine Technology: